PARSIPPANY, N.J., April 24, 2017 /PRNewswire/ -- Interpace
Diagnostics Group, Inc. (NASDAQ: IDXG) (the "Company"), A fully
integrated commercial company that provides clinically useful
molecular diagnostic tests and pathology services, is scheduled to
present at RedChip's Global Online Growth Conference on
Wednesday, April 26, 2017, at
1:30 p.m. Eastern time. The
presentation can be viewed at www.RedChip.com. A live Q&A
session will follow the investor
presentation.
RedChip's Global Online Growth Conference brings together
investors and executives of leading microcap companies,
representing a broad spectrum of industries and sectors, including
oil & gas, technology, mining, healthcare, consumer goods,
energy, and more. More than 10,000 investors attend RedChip's
microcap conference series each year.
No registration is required to participate in the conference.
Start times are subject to change.
About Interpace Diagnostics Group, Inc.
Interpace is a fully integrated commercial company that provides
clinically useful molecular diagnostic tests and pathology services
for evaluating risk of cancer by leveraging the latest technology
in personalized medicine for better patient diagnosis and
management. The Company currently has three commercialized
molecular tests: PancraGEN®, for the evaluation of pancreatic cysts
and assessment of risk of concomitant or subsequent cancer;
ThyGenX®, for the diagnosis of thyroid cancer from thyroid nodules
utilizing a next generation sequencing assay; and ThyraMIR®, for
the diagnosis of thyroid cancer from thyroid nodules utilizing a
proprietary gene expression assay. Interpace's mission is to
provide personalized medicine through molecular diagnostics and
innovation to advance patient care based on rigorous science.
Contact:
Interpace Diagnostics
Investor Relations:
Paul Kuntz
RedChip Companies
Paul@Redchip.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/interpace-diagnostics-to-present-at-redchips-global-online-growth-conference-300444075.html
SOURCE Interpace Diagnostics Group, Inc.